Estrogen and Skin

Therapeutic Options


Aging of the skin is associated with skin thinning, atrophy, dryness, wrinkling, and delayed wound healing. These undesirable aging effects are exacerbated by declining estrogen levels in postmenopausal women. With the rise in interest in long-term postmenopausal skin management, studies on the restorative benefits that estrogen may have on aged skin have expanded. Systemic estrogen replacement therapy (ERT) has been shown to improve some aspects of skin. Estrogen restores skin thickness by increasing collagen synthesis while limiting excessive collagen degradation. Wrinkling is improved following estrogen treatment since estrogen enhances the morphology and synthesis of elastic fibers, collagen type III, and hyaluronic acids. Dryness is also alleviated through increased water-holding capacity, increased sebum production, and improved barrier function of the skin. Furthermore, estrogen modulates local inflammation, granulation, re-epithelialization, and possibly wound contraction, which collectively accelerates wound healing at the expense of forming lower quality scars.

Despite its promises, long-term ERT has been associated with harmful systemic effects. In the search for safe and effective alternatives with more focused effects on the skin, topical estrogens, phytoestrogens, and tissuespecific drugs called selective estrogen receptor modulators (SERMs) have been explored. We discuss the promises and challenges of utilizing topical estrogens, SERMs, and phytoestrogens in postmenopausal skin management.

This is a preview of subscription content, log in to check access.

Table I
Table II


  1. 1.

    World Health Organization. Fact sheet number 252, 2000 [online]. Available from URL: ( [Accessed 2010 Jun 28]

  2. 2.

    Central Intelligence Agency. The world fact book, 2010 [online]. Available from URL: ( [Accessed 2010 Jul 1]

  3. 3.

    World Health Organization. Women, ageing and health: a framework for action, 2007 [online]. Available from URL: ( [Accessed 2010 Jul 1]

  4. 4.

    Raine-Fenning NJ, Brincat MP, Muscat-Baron Y. Skin aging and menopause: implications for treatment. Am J Clin Dermatol 2003; 4 (6): 371–8

    PubMed  Article  Google Scholar 

  5. 5.

    Hall G, Phillips TJ. Estrogen and skin: the effects of estrogen,menopause, and hormone replacement therapy on the skin. J Am Acad Dermatol 2005 Oct; 53 (4): 555–68, quiz 569-72

  6. 6.

    Albright F, Smith PH, Richardson AM. Postmenopausal osteoporosis: its clinical features. JAMA 1941; (116): 2465–74

    Article  Google Scholar 

  7. 7.

    Palacios S. Current perspectives on the benefits of HRT in menopausal women. Maturitas 1999 Nov; 33 Suppl. 1: S1–13

    Google Scholar 

  8. 8.

    Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal womenwith hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 2004 Apr 14; 291 (14): 1701–12

  9. 9.

    Slominski A. Neuroendocrine system of the skin. Dermatology 2005; 211 (3): 199–208

    PubMed  Article  Google Scholar 

  10. 10.

    Nelson LR, Bulun SE. Estrogen production and action. J AmAcad Dermatol 2001 Sep; 45 (3 Suppl.): S116–24

  11. 11.

    Shah MG, Maibach HI. Estrogen and skin: an overview. Am J Clin Dermatol 2001; 2 (3): 143–50

    PubMed  Article  CAS  Google Scholar 

  12. 12.

    Prentice RL, Manson JE, Langer RD, et al. Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol 2009 Jul 1; 170 (1): 12–23

  13. 13.

    Brandenberger AW, Tee MK, Lee JY, et al. Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta)mRNAin the midgestational human fetus. J Clin Endocrinol Metab 1997 Oct; 82 (10): 3509–12

  14. 14.

    Pelletier G, Ren L. Localization of sex steroid receptors in human skin. Histol Histopathol 2004 Apr; 19 (2): 629–36

  15. 15.

    Enmark E, Pelto-Huikko M, Grandien K, et al. Human estrogen receptor beta-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 1997 Dec; 82 (12): 4258–65

    Google Scholar 

  16. 16.

    Stevenson S, Thornton J. Effect of estrogens on skin aging and the potential role of SERMs. Clin Interv Aging 2007; 2 (3): 283–97

    PubMed  CAS  Google Scholar 

  17. 17.

    Lubahn DB, Moyer JS, Golding TS, et al. Alteration of reproductive function but not prenatal sexual development after insertional disruption of the mouse estrogen receptor gene. Proc Natl Acad Sci USA 1993 Dec 1; 90 (23): 11162–6

  18. 18.

    Couse JF, Lindzey J, Grandien K, et al. Tissue distribution and quantitative analysis of estrogen receptor-alpha (ERalpha) and estrogen receptor-beta (ERbeta) messenger ribonucleic acid in the wild-type and ERalphaknockout mouse. Endocrinology 1997 Nov; 138 (11): 4613–21

    Google Scholar 

  19. 19.

    Kuiper GG, Carlsson B, Grandien K, et al. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 1997 Mar; 138 (3): 863–70

  20. 20.

    Thornton MJ, Taylor AH, Mulligan K, et al. Oestrogen receptor beta is the predominant oestrogen receptor in human scalp skin. Exp Dermatol 2003 Apr; 12 (2): 181–90

    Google Scholar 

  21. 21.

    Verdier-Sevrain S, Yaar M, Cantatore J, et al. Estradiol induces proliferation of keratinocytes via a receptor mediated mechanism. FASEB J 2004 Aug; 18 (11): 1252–4

    Google Scholar 

  22. 22.

    Heard DJ, Norby PL, Holloway J, et al. Human ERRgamma, a third member of the estrogen receptor-related receptor (ERR) subfamily of orphan nuclear receptors: tissue-specific isoforms are expressed during development and in the adult. Mol Endocrinol 2000 Mar; 14 (3): 382–92

  23. 23.

    Truss M, Beato M. Steroid hormone receptors: interaction with deoxyribonucleic acid and transcription factors. Endocr Rev 1993 Aug; 14 (4): 459–79

  24. 24.

    Cheskis BJ, Greger JG, Nagpal S, et al. Signaling by estrogens. J Cell Physiol 2007 Dec; 213 (3): 610–7

  25. 25.

    Fu XD, Simoncini T. Extra-nuclear signaling of estrogen receptors. IUBMB Life 2008 Aug; 60 (8): 502–10

    Google Scholar 

  26. 26.

    Simoncini T, Genazzani AR. Non-genomic actions of sex steroid hormones. Eur J Endocrinol 2003 Mar; 148 (3): 281–92

  27. 27.

    Le Mellay V, Lasmoles F, Lieberherr M. Galpha(q/11) and gbetagamma proteins and membrane signaling of calcitriol and estradiol. J Cell Biochem 1999 Oct 1; 75 (1): 138–46

  28. 28.

    Kelly MJ, Lagrange AH, Wagner EJ, et al. Rapid effects of estrogen to modulateGprotein-coupled receptors via activation of protein kinase Aand protein kinase C pathways. Steroids 1999 Jan-Feb; 64 (1-2): 64–75

  29. 29.

    Bouskine A, Nebout M, Mograbi B, et al. Estrogens promote human testicular germ cell cancer through a membrane-mediated activation of extracellular regulated kinase and protein kinase A. Endocrinology 2008 Feb; 149 (2): 565–73

  30. 30.

    Le Mellay V, Grosse B, Lieberherr M. Phospholipase C beta and membrane action of calcitriol and estradiol. J Biol Chem 1997 May 2; 272 (18): 11902–7

  31. 31.

    Li L, Hisamoto K, Kim KH, et al. Variant estrogen receptor-c-Src molecular interdependence and c-Src structural requirements for endothelial NO synthase activation. Proc Natl Acad Sci U SA 2007 Oct 16; 104 (42): 16468–73

  32. 32.

    Shaul PW. Rapid activation of endothelial nitric oxide synthase by estrogen. Steroids 1999 Jan-Feb; 64 (1-2): 28–34

  33. 33.

    Brincat M, Kabalan S, Studd JW, et al. A study of the decrease of skin collagen content, skin thickness, and bone mass in the postmenopausal woman. Obstet Gynecol 1987 Dec; 70 (6): 840–5

    Google Scholar 

  34. 34.

    McConkey B, Fraser GM, Bligh AS. Transparent skin and osteoporosis. Lancet 1963; I: 693–5

    Article  Google Scholar 

  35. 35.

    Black M, Bottoms E, Shuster S. Changes in skin collagen and thickness in endocrine disease [abstract]. Eur J Clin Invest 1970; 1: 127

    Google Scholar 

  36. 36.

    Affinito P, Palomba S, Sorrentino C, et al. Effects of postmenopausal hypoestrogenism on skin collagen. Maturitas 1999 Dec 15; 33 (3): 239–47

  37. 37.

    Maheux R, Naud F, Rioux M, et al. A randomized, double-blind, placebocontrolled study on the effect of conjugated estrogens on skin thickness. Am J Obstet Gynecol 1994 Feb; 170 (2): 642–9

  38. 38.

    Callens A, Vaillant L, Lecomte P, et al. Does hormonal skin aging exist? A study of the influence of different hormone therapy regimens on the skin of postmenopausal women using non-invasive measurement techniques. Dermatology 1996; 193 (4): 289–94

    PubMed  Article  CAS  Google Scholar 

  39. 39.

    Sauerbronn AV, Fonseca AM, Bagnoli VR, et al. The effects of systemic hormonal replacement therapy on the skin of postmenopausal women. Int J Gynaecol Obstet 2000 Jan; 686 (1): 35–41

    Google Scholar 

  40. 40.

    Sator PG, Sator MO, Schmidt JB, et al. A prospective, randomized, doubleblind, placebo-controlled study on the influence of a hormone replacement therapy on skin aging in postmenopausal women. Climacteric 2007 Aug; 10 (4): 320–34

  41. 41.

    Savvas M, Bishop J, Laurent G, et al. Type III collagen content in the skin of postmenopausal women receiving oestradiol and testosterone implants. Br J Obstet Gynaecol 1993 Feb; 100 (2): 154–6

    Google Scholar 

  42. 42.

    Castelo-Branco C, Duran M, Gonzalez-Merlo J. Skin collagen changes related to age and hormone replacement therapy. Maturitas 1992 Oct; 15 (2): 113–9

  43. 43.

    Haapasaari KM, Raudaskoski T, Kallioinen M, et al. Systemic therapy with estrogen or estrogen with progestin has no effect on skin collagen in postmenopausal women. Maturitas 1997 Jun; 27 (2): 153–62

  44. 44.

    Bolognia JL, Braverman IM, Rousseau ME, et al. Skin changes in menopause. Maturitas 1989 Dec; 11 (4): 295–304

  45. 45.

    Varila E, Rantala I, Oikarinen A, et al. The effect of topical oestradiol on skin collagen of postmenopausal women. Br J Obstet Gynaecol 1995 Dec; 102 (12): 985–9

    Google Scholar 

  46. 46.

    Creidi P, Faivre B, Agache P, et al. Effect of a conjugated oestrogen (Premarin) cream on ageing facial skin: a comparative study with a placebo cream. Maturitas 1994 Oct; 19 (3): 211–23

  47. 47.

    Rittie L, Kang S, Voorhees JJ, et al. Induction of collagen by estradiol: difference between sun-protected and photodamaged human skin in vivo. Arch Dermatol 2008 Sep; 144 (9): 1129–40

    Google Scholar 

  48. 48.

    Son ED, Lee JY, Lee S, et al. Topical application of 17beta-estradiol increases extracellular matrix protein synthesis by stimulating tgf-Beta signaling in aged human skin in vivo. J Invest Dermatol 2005 Jun; 124 (6): 1149–61

  49. 49.

    Schmidt JB, Binder M, Demschik G, et al. Treatment of skin aging with topical estrogens. Int J Dermatol 1996 Sep; 35 (9): 669–74

    Google Scholar 

  50. 50.

    Patriarca MT, Goldman KZ, Dos Santos JM, et al. Effects of topical estradiol on the facial skin collagen of postmenopausal women under oral hormone therapy: a pilot study. Eur J Obstet Gynecol Reprod Biol 2007 Feb; 130 (2): 202–5

    Google Scholar 

  51. 51.

    Brincat M, Moniz CJ, Studd JW, et al. Long-term effects of the menopause and sex hormones on skin thickness. Br J Obstet Gynaecol 1985 Mar; 92 (3): 256–9

    Google Scholar 

  52. 52.

    Punnonen R, Lovgren T, Kouvonen I. Demonstration of estrogen receptors in the skin. J Endocrinol Invest 1980 Jul-Sep; 3 (3): 217–21

  53. 53.

    Stevenson S, Nelson LD, Sharpe DT, et al. 17 beta-estradiol regulates the secretion of TGF-beta by cultured human dermal fibroblasts. J Biomater Sci Polym Ed 2008; 19 (8): 1097–109

    PubMed  Article  CAS  Google Scholar 

  54. 54.

    Tomaszewski J, Adamiak A, Skorupski P, et al. Effect of 17 beta-estradiol and phytoestrogen daidzein on the proliferation of pubocervical fascia and skin fibroblasts derived from women suffering from stress urinary incontinence. Ginekol Pol 2003 Oct; 74 (10): 1410–4

    Google Scholar 

  55. 55.

    Moraes AB, Haidar MA, Soares Junior JM, et al. The effects of topical isoflavones on postmenopausal skin: double-blind and randomized clinical trial of efficacy. Eur J Obstet Gynecol Reprod Biol 2009 Oct; 146 (2): 188–92

  56. 56.

    Pirila E, Ramamurthy N, Maisi P, et al. Wound healing in ovariectomized rats: effects of chemically modified tetracycline (CMT-8) and estrogen on matrix metalloproteinases -8, -13 and type I collagen expression. Curr Med Chem 2001 Feb; 8 (3): 281–94

    Google Scholar 

  57. 57.

    Chang KC, Wang Y, Oh IG, et al. Estrogen receptor beta is a novel therapeutic target for photoaging. Mol Pharmacol 2010 May; 77 (5): 744–50

    Google Scholar 

  58. 58.

    Dunn LB, Damesyn M, Moore AA, et al. Does estrogen prevent skin aging? Results from the First National Health and Nutrition Examination Survey (NHANES I). Arch Dermatol 1997 Mar; 133 (3): 339–42

  59. 59.

    Grosman N, Hvidberg E, Schou J. The effect of oestrogenic treatment on the acid mucopolysaccharide pattern in skin of mice. Acta Pharmacol Toxicol (Copenh) 1971; 30 (5): 458–64

    Article  CAS  Google Scholar 

  60. 60.

    Grosman N. Study on the hyaluronic acid-protein complex, the molecular size of hyaluronic acid and the exchangeability of chloride in skin of mice before and after oestrogen treatment. Acta Pharmacol Toxicol (Copenh) 1973; 33 (3): 201–8

    Article  CAS  Google Scholar 

  61. 61.

    Uzuka M, Nakajima K, Ohta S, et al. Induction of hyaluronic acid synthetase by estrogen in the mouse skin. Biochim Biophys Acta 1981 Apr 3; 673 (4): 387–93

  62. 62.

    Pochi PE, Strauss JS, Downing DT. Age-related changes in sebaceous gland activity. J Invest Dermatol 1979 Jul; 73 (1): 108–11

    Google Scholar 

  63. 63.

    Pierard-Franchimont C, Pierard GE. Postmenopausal aging of the sebaceous follicle: a comparison between women receiving hormone replacement therapy or not. Dermatology 2002; 204 (1): 17–22

    PubMed  Article  CAS  Google Scholar 

  64. 64.

    Makrantonaki E, Vogel K, Fimmel S, et al. Interplay of IGF-I and 17betaestradiol at age-specific levels in human sebocytes and fibroblasts in vitro. Exp Gerontol 2008 Oct; 43 (10): 939–46

    Google Scholar 

  65. 65.

    Smith TM, Gilliland K, Clawson GA, et al. IGF-1 induces SREBP-1 expression and lipogenesis in SEB-1 sebocytes via activation of the phosphoinositide 3-kinase/Akt pathway. J Invest Dermatol 2008 May; 128 (5): 1286–93

    Google Scholar 

  66. 66.

    Hanley K, Rassner U, Jiang Y, et al. Hormonal basis for the gender difference in epidermal barrier formation in the fetal rat: acceleration by estrogen and delay by testosterone. J Clin Invest 1996 Jun 1; 97 (11): 2576–84

  67. 67.

    Pierard-Franchimont C, Letawe C, Goffin V, et al. Skin water-holding capacity and transdermal estrogen therapy for menopause: a pilot study. Maturitas 1995 Sep; 22 (2): 151–4

  68. 68.

    Paquet F, Pierard-Franchimont C, Fumal I, et al. Sensitive skin at menopause; dew point and electrometric properties of the stratum corneum. Maturitas 1998 Jan 12; 28 (3): 221–7

  69. 69.

    Denda M, Koyama J, Hori J, et al. Age- and sex-dependent change in stratum corneum sphingolipids. Arch Dermatol Res 1993; 285 (7): 415–7

    PubMed  Article  CAS  Google Scholar 

  70. 70.

    Misra M, Feinberg C, Matzke M, et al. Effect of hormone replacement therapy on epidermal barrier lipids. Int J Cosmet Sci 2006 Oct; 28 (5): 335–42

  71. 71.

    Contet-Audonneau JL, Jeanmaire C, Pauly G. A histological study of human wrinkle structures: comparison between sun-exposed areas of the face, with or without wrinkles, and sun-protected areas. Br J Dermatol 1999 Jun; 140 (6): 1038–47

    Google Scholar 

  72. 72.

    Bosset S, Barre P, Chalon A, et al. Skin ageing: clinical and histopathologic study of permanent and reducible wrinkles. Eur J Dermatol 2002 May-Jun; 12 (3): 247–52

    Google Scholar 

  73. 73.

    Tsukahara K, Nakagawa H, Moriwaki S, et al. Ovariectomy is sufficient to accelerate spontaneous skin ageing and to stimulate ultraviolet irradiationinduced photoageing ofmurine skin. Br J Dermatol 2004 Nov; 151 (5): 984–94

    Google Scholar 

  74. 74.

    Sumino H, Ichikawa S, Abe M, et al. Effects of aging, menopause, and hormone replacement therapy on forearm skin elasticity in women. J Am Geriatr Soc 2004 Jun; 52 (6): 945–9

  75. 75.

    Pierard GE, Letawe C, Dowlati A, et al. Effect of hormone replacement therapy for menopause on the mechanical properties of skin. J Am Geriatr Soc 1995 Jun; 43 (6): 662–5

    Google Scholar 

  76. 76.

    Sator PG, Schmidt JB, Sator MO, et al. The influence of hormone replacement therapy on skin ageing: a pilot study. Maturitas 2001 Jul 25; 39 (1): 43–55

  77. 77.

    Wolff EF, Narayan D, Taylor HS. Long-term effects of hormone therapy on skin rigidity and wrinkles. Fertil Steril 2005 Aug; 84 (2): 285–8

    Google Scholar 

  78. 78.

    Punnonen R, Vaajalahti P, Teisala K. Local oestriol treatment improves the structure of elastic fibers in the skin of postmenopausal women. Ann Chir Gynaecol Suppl 1987; 202: 39–41

    PubMed  CAS  Google Scholar 

  79. 79.

    Phillips TJ, Symons J, Menon S; HT Study Group. Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women. J Am Acad Dermatol 2008 Sep; 59 (3): 397–404.e3

  80. 80.

    Castelo-Branco C, Figueras F, Martinez de Osaba MJ, et al. Facial wrinkling in postmenopausal women: effects of smoking status and hormone replacement therapy. Maturitas 1998 May 20; 29 (1): 75–86

  81. 81.

    Farage MA, Neill S, MacLean AB. Physiological changes associated with the menstrual cycle: a review. Obstet Gynecol Surv 2009 Jan; 64 (1): 58–72

    Google Scholar 

  82. 82.

    Muizzuddin N, Marenus KD, Schnittger SF, et al. Effect of systemic hormonal cyclicity on skin. J Cosmet Sci 2005 Sep-Oct; 56 (5): 311–21

  83. 83.

    Eisenbeiss C, Welzel J, Schmeller W. The influence of female sex hormones on skin thickness: evaluation using 20 MHz sonography. Br J Dermatol 1998 Sep; 139 (3): 462–7

    Google Scholar 

  84. 84.

    Berardesca E, Gabba P, Farinelli N, et al. Skin extensibility time in women: changes in relation to sex hormones. Acta Derm Venereol 1989; 69 (5): 431–3

    PubMed  CAS  Google Scholar 

  85. 85.

    Agner T, Damm P, Skouby SO. Menstrual cycle and skin reactivity. J Am Acad Dermatol 1991 Apr; 24 (4): 566–70

  86. 86.

    Harvell J, Hussona-Saeed I, Maibach HI. Changes in transepidermal water loss and cutaneous blood flow during the menstrual cycle. Contact Dermatitis 1992 Nov; 27 (5): 294–301

    Google Scholar 

  87. 87.

    Ashcroft GS, Dodsworth J, van Boxtel E, et al. Estrogen accelerates cutaneous wound healing associated with an increase in TGF-beta1 levels. Nat Med 1997 Nov; 3 (11): 1209–15

    Google Scholar 

  88. 88.

    Ashcroft GS, Greenwell-Wild T, Horan MA, et al. Topical estrogen accelerates cutaneous wound healing in aged humans associated with an altered inflammatory response. Am J Pathol 1999 Oct; 155 (4): 1137–46

    Google Scholar 

  89. 89.

    Hardman MJ, Ashcroft GS. Estrogen, not intrinsic aging, is the major regulator of delayed human wound healing in the elderly [abstract]. Genome Biol 2008; 9 (5): R80

    Article  Google Scholar 

  90. 90.

    Gulshan S, McCruden AB, Stimson WH. Oestrogen receptors in macrophages. Scand J Immunol 1990 Jun; 31 (6): 691–7

    Google Scholar 

  91. 91.

    Razandi M, Pedram A, Merchenthaler I, et al. Plasma membrane estrogen receptors exist and functions as dimers. Mol Endocrinol 2004 Dec; 18 (12): 2854–65

  92. 92.

    Ashcroft GS, Mills SJ, Lei K, et al. Estrogen modulates cutaneous wound healing by downregulating macrophage migration inhibitory factor. J Clin Invest 2003 May; 111 (9): 1309–18

    Google Scholar 

  93. 93.

    Hardman MJ, Waite A, Zeef L, et al. Macrophage migration inhibitory factor: a central regulator of wound healing. Am J Pathol 2005 Dec; 167 (6): 1561–74

    Google Scholar 

  94. 94.

    Morales DE, McGowan KA, Grant DS, et al. Estrogen promotes angiogenic activity in human umbilical vein endothelial cells in vitro and in a murine model. Circulation 1995 Feb 1; 91 (3): 755–63

  95. 95.

    Le Poole IC, Boyce ST. Keratinocytes suppress transforming growth factorbeta1 expression by fibroblasts in cultured skin substitutes. Br J Dermatol 1999 Mar; 140 (3): 409–16

    Google Scholar 

  96. 96.

    Levine JH, Moses HL, Gold LI, et al. Spatial and temporal patterns of immunoreactive transforming growth factor beta 1, beta 2, and beta 3 during excisional wound repair. Am J Pathol 1993 Aug; 143 (2): 368–80

    Google Scholar 

  97. 97.

    Urano R, Sakabe K, Seiki K, et al. Female sex hormone stimulates cultured human keratinocyte proliferation and its RNA- and protein-synthetic activities. J Dermatol Sci 1995 May; 9 (3): 176–84

    Google Scholar 

  98. 98.

    Kanda N, Watanabe S. 17 beta-estradiol stimulates the growth of human keratinocytes by inducing cyclin D2 expression. J Invest Dermatol 2004 Aug; 123 (2): 319–28

    Google Scholar 

  99. 99.

    Shah M, Foreman DM, Ferguson MW. Control of scarring in adult wounds by neutralising antibody to transforming growth factor beta. Lancet 1992 Jan 25; 339 (8787): 213–4

  100. 100.

    Whitby DJ, Ferguson MW. Immunohistochemical localization of growth factors in fetal wound healing. Dev Biol 1991 Sep; 147 (1): 207–15

    Google Scholar 

  101. 101.

    Makela S, Santti R, Salo L, et al. Phytoestrogens are partial estrogen agonists in the adult male mouse. Environ Health Perspect 1995 Oct; 103 Suppl. 7: 123–7

    Google Scholar 

  102. 102.

    Bowers JL, Tyulmenkov VV, Jernigan SC, et al. Resveratrol acts as a mixed agonist/antagonist for estrogen receptors alpha and beta. Endocrinology 2000 Oct; 141 (10): 3657–67

    Google Scholar 

  103. 103.

    Jacobs A, Wegewitz U, Sommerfeld C, et al. Efficacy of isoflavones in relieving vasomotor menopausal symptoms: a systematic review. Mol Nutr Food Res 2009 Sep; 53 (9): 1084–97

    Google Scholar 

  104. 104.

    Lichtenstein AH. Soy protein, isoflavones and cardiovascular disease risk. J Nutr 1998 Oct; 128 (10): 1589–92

  105. 105.

    Verma SP, Goldin BR. Effect of soy-derived isoflavonoids on the induced growth of MCF-7 cells by estrogenic environmental chemicals. Nutr Cancer 1998; 30 (3): 232–9

    PubMed  Article  CAS  Google Scholar 

  106. 106.

    Kuiper GG, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998 Oct; 139 (10): 4252–63

  107. 107.

    Harris DM, Besselink E, Henning SM, et al. Phytoestrogens induce differential estrogen receptor alpha- or beta-mediated responses in transfected breast cancer cells. Exp Biol Med (Maywood) 2005 Sep; 230 (8): 558–68

    Google Scholar 

  108. 108.

    Wei H, Saladi R, Lu Y, et al. Isoflavone genistein: photoprotection and clinical implications in dermatology. J Nutr 2003 Nov; 133 (11 Suppl. 1): 3811S–9S

    Google Scholar 

  109. 109.

    Moore JO, Wang Y, Stebbins WG, et al. Photoprotective effect of isoflavone genistein on ultraviolet B-induced pyrimidine dimer formation and PCNA expression in human reconstituted skin and its implications in dermatology and prevention of cutaneous carcinogenesis. Carcinogenesis 2006 Aug; 27 (8): 1627–35

  110. 110.

    Circosta C, De Pasquale R, Palumbo DR, et al. Effects of isoflavones from red clover (Trifolium pratense) on skin changes induced by ovariectomy in rats. Phytother Res 2006 Dec; 20 (12): 1096–9

    Google Scholar 

  111. 111.

    Izumi T, Saito M, Obata A, et al. Oral intake of soy isoflavone aglycone improves the aged skin of adult women. J Nutr Sci Vitaminol (Tokyo) 2007 Feb; 53 (1): 57–62

    Google Scholar 

  112. 112.

    Miyazaki K, Hanamizu T, Iizuka R, et al. Genistein and daidzein stimulate hyaluronic acid production in transformed human keratinocyte culture and hairless mouse skin. Skin Pharmacol Appl Skin Physiol 2002 May-Jun; 15 (3): 175–83

  113. 113.

    Hardman MJ, Emmerson E, Campbell L, et al. Selective estrogen receptor modulators accelerate cutaneous wound healing in ovariectomized female mice. Endocrinology 2008 Feb; 149 (2): 551–7

  114. 114.

    Surazynski A, Jarzabek K, Haczynski J, et al. Differential effects of estradiol and raloxifene on collagen biosynthesis in cultured human skin fibroblasts. Int J Mol Med 2003 Nov; 12 (5): 803–9

    Google Scholar 

  115. 115.

    Sumino H, Ichikawa S, Kasama S, et al. Effects of raloxifene and hormone replacement therapy on forearm skin elasticity in postmenopausal women. Maturitas 2009 Jan 20; 62 (1): 53–7

  116. 116.

    Hu D, Hughes MA, Cherry GW. Topical tamoxifen: a potential therapeutic regime in treating excessive dermal scarring? Br J Plast Surg 1998 Sep; 51 (6): 462–9

  117. 117.

    Mikulec AA, Hanasono MM, Lum J, et al. Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts. Arch Facial Plast Surg 2001 Apr-Jun; 3 (2): 111–4

  118. 118.

    Ruffy MB, Kunnavatana SS, Koch RJ. Effects of tamoxifen on normal human dermal fibroblasts. Arch Facial Plast Surg 2006 Sep-Oct; 8 (5): 329–32

  119. 119.

    Thompson Z, Maibach HI. Biological effects of estrogen on skin. In: Farage MA, Miller KW, Maibach HI, editors. Textbook of aging skin. 1st ed. Berlin, Heidelberg: Springer-Verlag, 2010: 361–7

    Google Scholar 

Download references


We respectfully acknowledge Ms Gloria Won, Research and Reference Librarian from H.M. Fishbon Memorial Library for her assistance in the relevant literature search. No sources of funding were used to prepare this review. The authors have no conflicts of interest that are directly relevant to the content of this review.

Author information



Corresponding author

Correspondence to Yu Yu Shu.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Shu, Y.Y., Maibach, H.I. Estrogen and Skin. Am J Clin Dermatol 12, 297–311 (2011).

Download citation


  • Postmenopausal Woman
  • Hyaluronic Acid
  • Hormone Replacement Therapy
  • Stratum Corneum
  • Raloxifene